Abstract:Key PointsThe liver provides a useful generic model of inflammation and repair, showing the complex interplay between the epithelial, inflammatory, myofibroblast and extracellular matrix (ECM) components of the mammalian wound-healing response. In almost all situations, fibrosis is preceded by inflammation and elements of both the innate and adaptive immune systems are crucial in regulating the fibrotic process.Following liver injury, pro-inflammatory mediators that are generated by cellular damage and stimulated immune cells, as well as growth factors and cytokines (including platelet-derived growth factor, connective tissue growth factor, transforming growth factor-β and interleukin-13), activate mesenchymal precursor cells in tissues and induce their transdifferentiation into myofibroblasts. Myofibroblasts are master regulators of the fibrotic response as a result of their acquisition of scar-producing, proliferative, migratory, contractile, immunomodulatory and phagocytic properties.Recent studies have used bone marrow transplantation techniques in reporter mice to show that, regardless of the aetiology or the duration of the injury, liver myofibroblasts are almost exclusively derived from the activation of resident mesenchymal cells. Perpetuation of myofibroblast fibrogenic activity is mediated through several positive feedback loops, involving the autocrine and paracrine effects of cytokines and growth factors, and cell–cell and cell–matrix interactions. Myofibroblasts themselves function as innate immune cells.The balance of T helper 1 (TH1) cell-mediated and TH2 cell-mediated adaptive immune responses, the influence of unconventional T cell subsets and the equilibrium between different pro-inflammatory (that is, pro-fibrotic) and pro-resolution macrophage populations determine whether the outcome of tissue injury is homeostatic and self-limited or whether it results in pathogenic scarring.Liver fibrosis in rodents and humans is a dynamic, bidirectional process that has an inherent capacity for recovery and remodelling. The loss of myofibroblasts from the hepatic scar and a crucial switch in macrophage phenotype to a pro-resolution cell type are important events in the regression of liver fibrosis that facilitate remodelling of the ECM.A considerable number of tractable therapeutic targets have been identified in liver fibrosis, but clinical trials of anti-fibrotic therapies have so far been unsuccessful. Identification of the core pathways in fibrosis is likely to yield greater success in clinical translation.

Liver Disease: Induction, Progression, Immunological Mechanisms, and Therapeutic Interventions

Cell therapy in end-stage liver disease: replace and remodel

Liver cirrhosis: molecular mechanisms and therapeutic interventions

Current Status and Future Prospects of Mesenchymal Stem Cell Therapy for Liver Fibrosis

Liver fibrosis and repair: immune regulation of wound healing in a solid organ

Liver fibrosis: Pathophysiology and clinical implications

Liver Injury and Regeneration: Current Understanding, New Approaches, and Future Perspectives

Mesenchymal stromal cells: promising treatment for liver cirrhosis

Therapeutic potential of stem cells in regeneration of liver in chronic liver diseases: Current perspectives and future challenges

Liver Fibrosis Resolution: from Molecular Mechanisms to Therapeutic Opportunities

Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets

Novel Immune Subsets and Related Cytokines: Emerging Players in the Progression of Liver Fibrosis

Molecular Mechanisms of Fibrosis in Cholestatic Liver Diseases and Regenerative Medicine-Based Therapies

Cellular and Molecular Mechanisms Underlying Liver Fibrosis Regression

Regulation of Progression and Resolution of Liver Fibrosis by Immune Cells

Liver regeneration and inflammation: from fundamental science to clinical applications

Cell-Based Regeneration and Treatment of Liver Diseases

Liver Fibrosis: From Pathogenesis to Novel Therapies

From Basic Science towards Clinical Progress, Focusing on the Central Role of Hepatic Stellate Cells

Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues